Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian J Druker

Showing results (1-10 of 318) with videos related to

Pageof 32
Sort By:
Oncogene|December 12, 2002
Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CMLBrian J Druker
Molecular Cancer Therapeutics|March 27, 2003
Overcoming resistance to imatinib by combining targeted agentsBrian J Druker
Seminars in Hematology|February 4, 2003
Imatinib alone and in combination for chronic myeloid leukemiaBrian J Druker
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2003
David A. Karnofsky Award lecture. Imatinib as a paradigm of targeted therapiesBrian J Druker
Nature Medicine|October 9, 2009
Perspectives on the development of imatinib and the future of cancer researchBrian J Druker
The New England Journal of Medicine|June 16, 2006
Circumventing resistance to kinase-inhibitor therapyBrian J Druker
Cell Cycle (Georgetown, Tex.)|July 16, 2004
Imatinib: paradigm or anomaly?Brian J Druker
Blood|December 10, 2008
Translation of the Philadelphia chromosome into therapy for CMLBrian J Druker
Drugs|December 12, 2001
Imatinib: A Viewpoint by Brian J. DrukerBrian J. Druker
Cancer Cell|June 28, 2002
Perspectives on the development of a molecularly targeted agentBrian J Druker
Pageof 32

Showing results (1-10 of 318) with videos related to

Sort By:
Pageof 32
Oncogene|December 12, 2002
Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CMLBrian J Druker
Molecular Cancer Therapeutics|March 27, 2003
Overcoming resistance to imatinib by combining targeted agentsBrian J Druker
Seminars in Hematology|February 4, 2003
Imatinib alone and in combination for chronic myeloid leukemiaBrian J Druker
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2003
David A. Karnofsky Award lecture. Imatinib as a paradigm of targeted therapiesBrian J Druker
Nature Medicine|October 9, 2009
Perspectives on the development of imatinib and the future of cancer researchBrian J Druker
The New England Journal of Medicine|June 16, 2006
Circumventing resistance to kinase-inhibitor therapyBrian J Druker
Cell Cycle (Georgetown, Tex.)|July 16, 2004
Imatinib: paradigm or anomaly?Brian J Druker
Blood|December 10, 2008
Translation of the Philadelphia chromosome into therapy for CMLBrian J Druker
Drugs|December 12, 2001
Imatinib: A Viewpoint by Brian J. DrukerBrian J. Druker
Cancer Cell|June 28, 2002
Perspectives on the development of a molecularly targeted agentBrian J Druker
Pageof 32